Torii Pharmaceuticals Start Phase II/III In Hyposensitization Therapy
02:00 EDT 2 Aug 2012 | Elsevier Business Intelligence
Torii Pharmaceuticals announced July 31 is started Phase II clinical trials for TO-203, a hyposensitization drug for allergic asthma and rhinitis caused by house dust mites. The sublingual tablets extract protein from the allergen.
Original Article: Torii Pharmaceuticals Start Phase II/III In Hyposensitization Therapy
More From BioPortfolio on "Torii Pharmaceuticals Start Phase II/III In Hyposensitization Therapy"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
